Answers are grounded in this paper and cite their sources.
Concurrent targeting of PI3K and IGFR signaling overcomes resistance in NSCLC, indicating strong therapeutic potential.
Concurrent targeting of PI3K and IR/IGF-1R signaling effectively overcomes adaptive resistance in PIK3CA-mutant NSCLC, supporting the rationale for further clinical evaluation of this combined therapeutic strategy.
No takes yet. Share an insight, caveat, or question.
El-Salam et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: